- Mark Zafereor
Dr. Mark Zafereo is an Associate Professor of Head and Neck Surgery at MD Anderson Cancer Center in Houston,
Texas. He is Section Chief of Head and Neck Endocrine Surgery and Associate Medical Director of the Endocrine
Center at MD Anderson Cancer Center.
Dr. Zafereo holds national committee appointments for the American Head and Neck Society, American Academy
of Otolaryngology-Head and Neck Surgery, and American Board of Otolaryngology-Head and Neck Surgery, and he
is a Past President of the Houston Society of Otolaryngology-Head and Neck Surgery.
He has published extensively on Thyroid and other Head & Neck cancers, speaking nationally and internationally.
His clinical practice focuses on patients afflicted with thyroid cancer and parathyroid neoplasms.
- R Michael Tuttle
Dr R Michael Tuttle, an Endocrinologist and Professor of Medicine at Memorial Sloan Kettering Cancer Center
in New York, designed and validated the first real time risk assessment model for thyroid cancer management
in which individual risk estimates are modified over time as a function of response to initial therapy.
In addition, his clinical studies have helped to define defined the role of recombinant human TSH as an adjuvant
for radioactive iodine therapy in both low risk and high risk patients and in the setting of radioactive iodine
avid distant metastases.
His research continues to center on important management aspects of thyroid cancer including efforts to better define
of risk of recurrence, risk of death, and the potential role for observation in low risk thyroid cancer. His clinical practice
is entirely devoted to patients with thyroid cancer with a particular emphasis on cases with aggressive disease and
complicated management issues.